TIDMORPH
RNS Number : 8541U
Open Orphan PLC
04 August 2022
Open Orphan plc
("Open Orphan" or the "Company")
GBP6.2m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, announces that hVIVO , a subsidiary of Open Orphan
plc, has signed a GBP6.2m contract with a US-based biotechnology
company to test its antiviral candidate using the hVIVO Influenza A
human challenge study model.
The human challenge study is expected to commence in H2 2022 and
will be conducted at hVIVO's state-of-the-art facilities in London.
The Company expects the revenue from the contract to be recognised
across 2022 and 2023.
The client has already published preliminary data to demonstrate
a favourable pharmacokinetic and safety profile. This candidate
exhibits a novel mechanism of action and differs from previously
approved drugs. This is an ideal time in the development of this
drug to conduct a challenge study.
This is the third significant influenza human challenge study
contract that Open Orphan has signed in 2022, as attention switches
to potential future outbreaks in this particular disease area.
Influenza is a serious global health threat with an estimated 1
billion cases per year, 3-5 million severe cases and 290,000 -
650,000 deaths per year.
hVIVO has three decades of experience and expertise in safely
conducting challenge studies across a range of respiratory viruses,
including various strains of influenza, respiratory syncytial virus
(RSV) and human rhinovirus (HRV - common cold virus), and asthma,
as well as malaria. In June 2022 , hVIVO announced that it is
developing the world's first SARS-CoV-2 Omicron human challenge
model.
Yamin 'Mo' Khan, Chief Executive Officer of Open Orphan, said :
"We are pleased to be working with this US-based client to test its
exciting lead influenza antiviral using our Influenza human
challenge study model. That the client has chosen us to run this
study is testament to our position as the world leader in testing
infectious and respiratory disease vaccines and antivirals using
challenge studies. Furthermore, the contract underlines the
increasing demand in the infectious disease clinical trial market,
which is expected to grow to a value of over $5.5 billion by
2027.
"With this increasing demand in mind, we expect to continue to
see our work coming from a broad range of infectious and
respiratory diseases, and from companies ranging from smaller
innovative biotechs to Big Pharma. "
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 (as implemented into
English law). With the publication of this announcement via a
Regulatory Information Service, this inside information is now
considered to be in the public domain.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com. By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
For further information please contact:
Open Orphan plc +44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
Liberum Capital (Nominated Adviser
and Joint Broker) +44 (0) 20 3100 2000
Ben Cryer/ Edward Mansfield/ Phil
Walker/ Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Phillip Marriage / +44 (0)7980 541 893 / +44 (0) 7867
Louis Ashe-Jepson 984 082 /
+44 (0)7747 515393
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
infectious and respiratory disease products using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases, including the
recently established COVID-19 model, and is developing a number of
new models, such as Malaria, to address the dramatic growth of the
global infectious disease market. The Paris and Breda offices have
over 25 years of experience providing drug development services
such as biometry, data management, statistics CMC, PK and medical
writing to third party clients as well as supporting the
London-based challenge studies.
Open Orphan runs challenge studies in London from its
Whitechapel quarantine clinic, its state-of-the-art QMB clinic with
its highly specialised on-site virology and immunology laboratory,
and its newly opened clinic in Plumbers Row. To recruit volunteers
/ patients for its studies, the Company leverages its unique
clinical trial recruitment capacity via its FluCamp volunteer
screening facilities in London and Manchester. The newly opened
facilities have expanded the scope of the business to enable the
offering of Phase I and Phase II vaccine field trials, PK studies,
bridging studies, and patient trials as part of large international
multi-centre studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological, and digital (wearable) biomarkers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTBKNBNKBKBNFK
(END) Dow Jones Newswires
August 04, 2022 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024